TY - JOUR
T1 - Association between antihypertensive medicine use and risk of ovarian cancer in women aged 50 years and older
AU - Tuesley, Karen M.
AU - Spilsbury, Katrina
AU - Webb, Penelope M.
AU - Protani, Melinda M.
AU - Dixon-Suen, Suzanne
AU - Pearson, Sallie Anne
AU - Donovan, Peter
AU - Coory, Michael D.
AU - Steer, Christopher B.
AU - Stewart, Louise M.
AU - Pandeya, Nirmala
AU - Jordan, Susan J.
N1 - Funding Information:
This work was supported by a project grant from the Australian National Health and Medical Research Council (NHMRC, APP1121151 ). PW was supported by NHMRC Investigator Grant GNT1173346 . NP’s salary was supported by a NHMRC grant ( APP1185416 ). KT was supported by an Australian Government Research Training Programme scholarship .
Publisher Copyright:
© 2023 The Authors
PY - 2023/10
Y1 - 2023/10
N2 - Background: Epithelial ovarian cancer (EOC) has few modifiable risk factors. There is evidence that some antihypertensive medicines may have cancer preventive and/or therapeutic actions; therefore, we assessed the associations between use of different antihypertensive medicines and risk of specific EOC histotypes. Methods: Our nested case-control study of linked administrative health data included 6070 Australian women aged over 50 years diagnosed with EOC from 2004 to 2013, and 30,337 matched controls. We used multivariable conditional logistic regression to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between ever use of each antihypertensive medicine group, including beta-adrenergic blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, and alpha blockers, and the risk of EOC overall and separately for the serous, endometrioid, mucinous, clear cell and other histotypes. Results: We found that most antihypertensive medicines were not associated with risk of EOC. However, women who used calcium channel blockers had a reduced risk of serous EOC (OR= 0.89, 95 % CI:0.81,0.98) and use of combination thiazide and potassium-sparing diuretics was associated with an increased risk of endometroid EOC (OR= 2.09, 95 % CI:1.15,3.82). Conclusion: Our results provide little support for a chemo-preventive role for most antihypertensives, however, the histotype-specific associations we found warrant further investigation.
AB - Background: Epithelial ovarian cancer (EOC) has few modifiable risk factors. There is evidence that some antihypertensive medicines may have cancer preventive and/or therapeutic actions; therefore, we assessed the associations between use of different antihypertensive medicines and risk of specific EOC histotypes. Methods: Our nested case-control study of linked administrative health data included 6070 Australian women aged over 50 years diagnosed with EOC from 2004 to 2013, and 30,337 matched controls. We used multivariable conditional logistic regression to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between ever use of each antihypertensive medicine group, including beta-adrenergic blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, and alpha blockers, and the risk of EOC overall and separately for the serous, endometrioid, mucinous, clear cell and other histotypes. Results: We found that most antihypertensive medicines were not associated with risk of EOC. However, women who used calcium channel blockers had a reduced risk of serous EOC (OR= 0.89, 95 % CI:0.81,0.98) and use of combination thiazide and potassium-sparing diuretics was associated with an increased risk of endometroid EOC (OR= 2.09, 95 % CI:1.15,3.82). Conclusion: Our results provide little support for a chemo-preventive role for most antihypertensives, however, the histotype-specific associations we found warrant further investigation.
KW - Adrenergic beta-antagonists
KW - Antihypertensive agents
KW - Calcium channel blockers
KW - Carcinoma, Ovarian epithelial
KW - Diuretics
UR - http://www.scopus.com/inward/record.url?scp=85169042824&partnerID=8YFLogxK
U2 - 10.1016/j.canep.2023.102444
DO - 10.1016/j.canep.2023.102444
M3 - Article
C2 - 37595337
AN - SCOPUS:85169042824
SN - 1877-7821
VL - 86
JO - Cancer Epidemiology
JF - Cancer Epidemiology
M1 - 102444
ER -